OBJECTIVES: The development of daptomycin resistance in Staphylococcus aureus is associated with clinical treatment failures. The mechanism(s) of such resistance have not been clearly defined. METHODS: We studied an isogenic daptomycin-susceptible (DAP(S)) and daptomycin-resistant (DAP(R)) S. aureus strain pair (616; 701) from a patient with relapsing endocarditis during daptomycin treatment, using comparative transcriptomic and proteomic techniques. RESULTS: Minor differences in the genome content were found between strains by DNA hybridization. Transcriptomic analyses identified a number of genes differentially expressed in important functional categories: cell division; metabolism of bacterial envelopes; and global regulation. Of note, the DAP(R) isolate exhibited reduced expression of the major cell wall autolysis gene coincident with the up-regulation of genes involved in cell wall teichoic acid production. Using quantitative (q)RT-PCR on the gene cadre putatively involved in cationic peptide resistance, we formulated a putative regulatory network compatible with microarray data sets, mainly implicating bacterial envelopes. Of interest, qRT-PCR of this same gene cadre from two distinct isogenic DAP(S)/DAP(R) clinical strain pairs revealed evidence of other strain-dependent networks operative in the DAP(R) phenotype. Comparative proteomics of 616 versus 701 revealed a differential abundance of proteins in various functional categories, including cell wall-associated targets and biofilm formation proteins. Phenotypically, strains 616 and 701 showed major differences in their ability to develop bacterial biofilms in the presence of the antibacterial lipid, oleic acid. CONCLUSIONS: Compatible with previous in vitro observations, in vivo-acquired DAP(R) in S. aureus is a complex, multistep phenomenon involving: (i) strain-dependent phenotypes; (ii) transcriptome adaptation; and (iii) modification of the lipid and protein contents of cellular envelopes.
OBJECTIVES: The development of daptomycin resistance in Staphylococcus aureus is associated with clinical treatment failures. The mechanism(s) of such resistance have not been clearly defined. METHODS: We studied an isogenic daptomycin-susceptible (DAP(S)) and daptomycin-resistant (DAP(R)) S. aureus strain pair (616; 701) from a patient with relapsing endocarditis during daptomycin treatment, using comparative transcriptomic and proteomic techniques. RESULTS: Minor differences in the genome content were found between strains by DNA hybridization. Transcriptomic analyses identified a number of genes differentially expressed in important functional categories: cell division; metabolism of bacterial envelopes; and global regulation. Of note, the DAP(R) isolate exhibited reduced expression of the major cell wall autolysis gene coincident with the up-regulation of genes involved in cell wall teichoic acid production. Using quantitative (q)RT-PCR on the gene cadre putatively involved in cationic peptide resistance, we formulated a putative regulatory network compatible with microarray data sets, mainly implicating bacterial envelopes. Of interest, qRT-PCR of this same gene cadre from two distinct isogenic DAP(S)/DAP(R) clinical strain pairs revealed evidence of other strain-dependent networks operative in the DAP(R) phenotype. Comparative proteomics of 616 versus 701 revealed a differential abundance of proteins in various functional categories, including cell wall-associated targets and biofilm formation proteins. Phenotypically, strains 616 and 701 showed major differences in their ability to develop bacterial biofilms in the presence of the antibacterial lipid, oleic acid. CONCLUSIONS: Compatible with previous in vitro observations, in vivo-acquired DAP(R) in S. aureus is a complex, multistep phenomenon involving: (i) strain-dependent phenotypes; (ii) transcriptome adaptation; and (iii) modification of the lipid and protein contents of cellular envelopes.
Authors: Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191
Authors: Carlo McCalla; Davida S Smyth; D Ashley Robinson; Judith Steenbergen; Steven A Luperchio; Pamela A Moise; Vance G Fowler; George Sakoulas Journal: Antimicrob Agents Chemother Date: 2008-07-07 Impact factor: 5.191
Authors: Patrice Francois; Antoine Huyghe; Yvan Charbonnier; Manuela Bento; Sébastien Herzig; Ivan Topolski; Bénédicte Fleury; Daniel Lew; Pierre Vaudaux; Stephan Harbarth; Willem van Leeuwen; Alex van Belkum; Dominique S Blanc; Didier Pittet; Jacques Schrenzel Journal: J Clin Microbiol Date: 2005-07 Impact factor: 5.948
Authors: Michael M Mwangi; Shang Wei Wu; Yanjiao Zhou; Krzysztof Sieradzki; Herminia de Lencastre; Paul Richardson; David Bruce; Edward Rubin; Eugene Myers; Eric D Siggia; Alexander Tomasz Journal: Proc Natl Acad Sci U S A Date: 2007-05-21 Impact factor: 11.205
Authors: Christoph M Ernst; Petra Staubitz; Nagendra N Mishra; Soo-Jin Yang; Gabriele Hornig; Hubert Kalbacher; Arnold S Bayer; Dirk Kraus; Andreas Peschel Journal: PLoS Pathog Date: 2009-11-13 Impact factor: 6.823
Authors: Nagendra N Mishra; James McKinnell; Michael R Yeaman; Aileen Rubio; Cynthia C Nast; Liang Chen; Barry N Kreiswirth; Arnold S Bayer Journal: Antimicrob Agents Chemother Date: 2011-06-27 Impact factor: 5.191
Authors: Andrew D Berti; Justine E Wergin; Gary G Girdaukas; Scott J Hetzel; George Sakoulas; Warren E Rose Journal: Antimicrob Agents Chemother Date: 2012-07-16 Impact factor: 5.191
Authors: Shrenik Mehta; Arabela X Cuirolo; Konrad B Plata; Sarah Riosa; Jared A Silverman; Aileen Rubio; Roberto R Rosato; Adriana E Rosato Journal: Antimicrob Agents Chemother Date: 2011-10-10 Impact factor: 5.191
Authors: Ute Bertsche; Christopher Weidenmaier; Daniel Kuehner; Soo-Jin Yang; Stefanie Baur; Stefanie Wanner; Patrice Francois; Jacques Schrenzel; Michael R Yeaman; Arnold S Bayer Journal: Antimicrob Agents Chemother Date: 2011-05-23 Impact factor: 5.191